NEWEST: a Phase II, randomised, neoadjuvant trial comparing fulvestrant 500 mg vs 250 mg in postmenopausal women with locally advanced, oestrogen receptor-positive (ER+) breast cancer

✍ Scribed by C. Singer; I. Kuter; R. Hegg; R. Badwe; N. Harbeck; J. Bines; E. Lowe

• Book ID: 119598037
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 63 KB
• Volume: 6
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(08)70543-3